Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 30;4(1):vdac154.
doi: 10.1093/noajnl/vdac154. eCollection 2022 Jan-Dec.

PD-L1 expression in breast cancer brain metastases

Rania Chehade  1 , Maleeha A Qazi  2 , Marguerite Ennis  3 , Arjun Sahgal  4   5 , Sunit Das  6 , Sharon Nofech-Mozes  7 , Katarzyna J Jerzak  4   8
Affiliations

PD-L1 expression in breast cancer brain metastases

Rania Chehade et al. Neurooncol Adv. .

Abstract

Background: To evaluate the potential intracranial efficacy of immunotherapy among patients with breast cancer brain metastases (BrM), we analyzed the immunohistochemical expression of programmed death-ligand 1 (PD-L1), a predictive biomarker of response to immunotherapy.

Methods: In this single-center retrospective cohort study, consecutive patients with breast cancer BrM (immunotherapy naïve) who underwent surgery for BrM at Sunnybrook Health Sciences Center between July 1999 and June 2013 were identified. PD-L1 expression by immunohistochemistry (IHC) was assessed on BrM samples in triplicate; PD-L1 positive status was defined as PD-L1 expression ≥1% on tumor-infiltrating cells as a percentage of tumor area using the Ventana SP142 antibody. Estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor (HER2) status was determined using 2018 ASCO/CAP guidelines.

Results: The median patient age at the time of BrM diagnosis was 52 (range 32-85). PD-L1 expression using the SP42 antibody was identified in 9 out of 59 (15.3%) breast cancer BrM. The frequency of PD-L1 positive BrM by subtype is as follows: TNBC (n = 3/12, 25.0%), HER2+/HR- (n = 3/14, 21.4%), HR+/HER2- (n = 2/18, 11.1%), and HER2+/HR+ (n = 1/14, 7.1%). 24-month brain-specific progression-free survival was 66.7% (95% CI 37.9%-100%) among patients with PD-L1 positive BrM versus 42% (95% CI 26.6%-67.3%) among those with PD-L1 negative BrM (log-rank P-value .142).

Conclusions: One in 7 patients in our cohort had PD-L1 positive BrM; this proportion was highest (25%) among those with TNBC. Intracranial efficacy of immunotherapy warrants further study, particularly among patients with treatment-naïve metastatic TNBC, for whom extracranial efficacy has already been established.

Keywords: PD-L1; brain metastases; breast cancer.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Kaplan Meier survival curve (A) bsPFS and (B) OS in BrM stratified by PD-L1 status. bsPFS, brain-specific progression-free survival; OS, overall survival.
See this image and copyright information in PMC

References

    1. Aversa C, Rossi V, Geuna E, et al. . Metastatic breast cancer subtypes and central nervous system metastases. Breast. 2014;23(5):623–628. - PubMed
    1. Kuksis M, Gao Y, Tran W, et al. . The incidence of brain metastases among patients with metastatic breast cancer: a systematic review and meta-analysis. Neuro Oncol. 2021;23(6):894–904. - PMC - PubMed
    1. Komorowski AS, Warner E, MacKay HJ, et al. . Incidence of brain metastases in nonmetastatic and metastatic breast cancer: is there a role for screening? Clin Breast Cancer. 2020;20(1):e54–e64. - PubMed
    1. Goldberg SB, Gettinger SN, Mahajan A, et al. . Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17(7):976–983. - PMC - PubMed
    1. Cortinovis D, Abbate M, Bidoli P, Capici S, Canova S. Targeted therapies and immunotherapy in non-small-cell lung cancer. Ecancermedicalscience. 2016;10:648. - PMC - PubMed

LinkOut - more resources